By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported a slight rise in its first-quarter revenues and a 6 percent increase in its net loss year over year.

The microRNA-based diagnostics firm reported total revenues of $27,000 for the three-month period ended March 31, compared to $17,000 for the first quarter of 2009.

Rosetta's net loss for the quarter was $3.6 million, or $.22 per share, compared to $3.4 million, or $.30 per share, for Q1 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.